Efficacy of a Novel Pleiotropic MMP-Inhibitor, CMC2.24, in a Long-Term Diabetes Rat Model with Severe Hyperglycemia-Induced Oral Bone Loss.

J Inflamm Res · 2023 · PMC9969803 · PMID 36860795

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The activated-form of MMP-9 (82 kDa) showed a trend (not statistically significant) of increase in the D group (increased to 158%) compared to non-diabetic controls, whereas the D+2.24 group exhibited levels similar to normal group ( Figure 3A ), a pattern similar to blood plasma.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.